De novo designed polypeptides that bind to IL-2 receptor β.sub.c heterodimer (IL-2Rβ.sub.c), IL-4 receptor α.sub.cheterodimer (IL-4Rα.sub.c), or IL-13 receptor α subunit (IL-13Rα) are disclosed, as are methods for using and designing the polypeptides.

This document relates to methods and materials for targeted expansion of regulatory T cells (T.sub.RegS). For example, one or more single-chain antibody/cytokine fusion proteins (immunocytokines) that can bind to a heterotrimeric receptor including an interleukin-2 receptor-α(IL-2Rα) polypeptide, an interleukin-2 receptor-β(IL-2Rβ) polypeptide, and a common gamma chain (γc) polypeptide (e.g., an IL-2Rα/IL-2Rβ/γc polypeptide complex) can be administered to a mammal to stimulate T.sub.RegS within the mammal to reduce or eliminate an immune response in that mammal. In some cases, methods and materials that can be used to treat a mammal having a condition that can benefit from reducing or eliminating an immune response within the mammal are provided. For example, one or more single-chain immunocytokines that can bind to an IL-2Rα/IL-2Rβ/γc polypeptide complex can be administered to a mammal having a condition that can benefit from reducing or eliminating an immune response to treat the mammal.

Aspects of the present disclosure include compositions having a plurality of individual polymeric nanowires. Individual polymeric nanowires according to embodiments include a bioactive compound. Methods for preparing and methods for administering the subject compositions of individual polymeric nanowires to a subject are also described. Kits having one or more components for practicing the subject methods are also provided.

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Provided herein are methods and devices related to inducing a population of self-renewing or senescent stem cells, to produce one or more beneficial factors for the treatment of a disease or disorder in an individual. Also provided are compositions and methods for inducing senescence, useful for inducing senescence in a population of stem cells, in order to produce one or more beneficial factors for the treatment of a disease or disorder in an individual. Methods and devices to control and customize the production of the beneficial factors for the requirements of a disease or disorder being treated are described. Also provided are factor production units for the production of the beneficial factors, and devices for the delivery of the beneficial factors to an individual in need.

Disclosed herein is a dual binding moiety that comprises non-CDR loops for masking the binding of a domain, such as a target antigen binding domain to its target, by steric occlusion and specific masking, and CDRs for binding bulk serum proteins. Pharmaceutical compositions comprising the dual binding moiety disclosed herein and methods of using such compositions are further provided.

Provided is an antibody that binds to human interleukin-2 (hIL-2), and more particularly to an anti-hIL-2 antibody that binds specifically to a particular epitope of hIL-2, thereby inhibiting the binding of the hIL-2 to CD25. The anti-hIL-2 antibody of the subject matter binds specifically to a particular epitope of hIL-2, thereby inhibiting the binding of the hIL-2 to CD25, thereby minimizing expansion of Treg cells. In addition, it stimulates the CD8.sup.+ T cells and NK cells that exhibit anti-tumor activity. Thus, the anti-hIL-2 antibody of the present invention is useful as a new anticancer therapeutic agent.

The invention relates to a human lnterieuldn-2 (hIL-2) specific monoclonal antibody (mAb), or antigen binding fragment thereof, the binding of which to hlL-2 inhibits binding of hlL-2 to CD25 and the antibody is characterized by any of the parameters: the variable chain of the mAb comprises the amino acid sequence of SEQ ID NO 005 or SEQ ID NO 006; the binding to hIL-2 is characterized by a dissociation constant (K.sub.D)≤7.5 nmol/L; the binding to hIL-2 is characterized by an off-rate (K.sub.off)≤1×10.sup.−4 s.sup.−1 and/or the antibody displays no measurable cross-reactivity to murine IL-2.

The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.

Compositions comprising TL1A-Ig fusion proteins and methods of their use, e.g., for the treatment of diseases and disorders associated with antigen-specific immune responses, are described. Also described are combination therapies that include the administration of a TNFRSF25 agonist and an interleukin (e.g., IL-2) and/or an mTOR inhibitor (e.g., rapamycin).